Immunotherapy Prostate Cancer Clinical Trials

Nutrition And Lifestyle Changes

Many studies have looked at the possible benefits of specific nutrients in helping to treat prostate cancer, although so far none have shown a clear benefit. Some compounds being studied include extracts from pomegranate, green tea, broccoli, turmeric, flaxseed, and soy.

One study has found that men who choose not to have treatment for their localized prostate cancer may be able to slow its growth with intensive lifestyle changes. The men in the study ate a vegan diet and exercised frequently. They also took part in support groups and yoga. After one year the men saw, on average, a slight drop in their PSA level. It isnt known if this effect will last since the report only followed the men for 1 year. The regimen may also be hard for some men to follow.

It’s important for men thinking about taking any type of nutritional supplement to talk to their health care team first. They can help you decide which ones you can use safely while avoiding those that might be harmful.

Is A Clinical Trial The Right Option For Your Prostate Cancer Treatment

Clinical trials are not only safe and carefully regulated, but also an important step in determining how a new treatment can best be used to help patients. During a clinical trial, investigators will learn:

• Which doses of the treatment are most effective
• Which patients respond best to the treatment
• Whether the treatment provides the best results on its own or when combined with other therapies
• What side effects might occur, and how they can be managed

As a National Cancer Institute-designed Comprehensive Cancer Center, Moffitt Cancer Center is constantly conducting clinical trials to study the newest treatments for prostate cancer. For instance, we have investigated the role of hormone therapy in patients with rising prostate-specific antigen levels after their first attempt at treatment, as well as the effectiveness of bone-strengthening therapies to help reduce the likelihood that prostate cancer will spread to the bones. These are just a small sampling of the trials weve conducted we continually strive to offer our patients more effective treatment options, and our robust clinical trials program is one of the main ways we are able to do so.

To learn more about our prostate cancer clinical trials, call or or submit a clinical trials inquiry form online. No referral is required our clinical trial navigators will be happy to help you find a trial that may suit your treatment goals.

Combination Of Bipolar Androgen Therapy And Nivolumab

Sorry, in progress, not accepting new patients

Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one novel androgen-receptor targeted therapy . Up to one taxane agent is permitted.

San Francisco, California

Also Check: Does Not Ejaculating Cause Prostate Cancer

Phase 3 Study Of Immunotherapy To Treat Advanced Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

First Posted : January 27, 2010Results First Posted : August 18, 2016Last Update Posted : August 18, 2016

Condition or disease Layout table for study information

Study Type :
Quadruple
Primary Purpose:	Treatment
Official Title:	Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer
Study Start Date :

Overall Survival Time OS was defined as the time from the date of randomization until the date of death. For participants without documentation of death, OS was censored at the last date the participant was known to be alive.

Progression-Free Survival Time Progression-free survival, as determined by the investigator, was defined as the time from randomization to the earliest date of confirmed Prostate-Specific Antigen progression, confirmed radiological progression, clinical deterioration, or death.

Transpelvic Magnetic Stimulation To Improve Urogenital Function

Sorry, accepting new patients by invitation only

After recruitment, 20 male patients will be assigned 1:1 to either age-matched control or age-matched intervention groups using computer-generated process, and baseline parameters will be established. All patients will be instructed by the investigators to perform standard of care pelvic floor exercise for the duration of the study. In addition, G2 patients will receive TPMS, while G1 patients will undergo sham treatment.

San Diego, California

Recommended Reading: How Long Can One Live With Prostate Cancer

A Study Of Niraparib In Combination With Abiraterone Acetate And Prednisone Versus Abiraterone Acetate And Prednisone For The Treatment Of Participants With Deleterious Germline Or Somatic Homologous Recombination Repair Gene

Sorry, not currently recruiting here

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair gene-mutated Metastatic Castration-Sensitive Prostate Cancer provides superior efficacy in improving radiographic progression-free survival .

San Francisco, California and other locations

Newer Treatments For Early

Researchers are looking at newer forms of treatment for early-stage prostate cancer. These new treatments could be used either as the first type of treatment or after unsuccessful radiation therapy.

One treatment, known as high-intensity focused ultrasound , destroys cancer cells by heating them with highly focused ultrasonic beams. This treatment has been used in some countries for a while, and is now available in the United States. Its safety and effectiveness are now being studied, although most doctors in the US dont consider it to be a proven first-line treatment for prostate cancer at this time.

You May Like: Can Enlarged Prostate Cause Back Pain

A Study Has Found That A Novel Immunotherapy Using The Natural Killer Cells Can Improve The Effectiveness Of Cancer Treatment

Scientists have found a novel immunotherapy that could bolster the effectiveness of cancer treatment, according to a study. Rather than rally T cells against cancer, scientists have used different human immune cells called natural killer cells as a novel means to fight cancer, according to a study.

The team of scientists at Albert Einstein College of Medicine described findings that could boost the impact of immune-checkpoint therapy, the study said. Findings have been published in The Journal of Clinical Investigation .

Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumour cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10 per cent to 30 per cent of treated patients experience long-term improvement, the study said.

“We believe the novel immunotherapy we have developed has great potential to move into clinical trials involving various types of cancer,” said study leader Xingxing Zang.

The surfaces of immune cells are studded with receptors known as ‘checkpoint’ proteins, which prevent immune cells from straying beyond their usual targets, which are pathogen-infected cells and cancer cells. When checkpoint receptors on immune cells bind with proteins expressed by the body’s own normal cells, the interaction puts the brakes on a possible immune-cell attack, the study explained.

A cancer-cell protein called PVR soon captured their attention.

Hyperpolarized Pyruvate Mr Imaging In Monitoring Patients With Prostate Cancer On Active Surveillance

Sorry, in progress, not accepting new patients

This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate magnetic resonance imaging works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.

San Francisco, California

Recommended Reading: When To Start Prostate Screening

Treating Prostate Cancer That Has Spread To The Bones

Doctors are studying the use ofradiofrequency ablation to help control pain in men whose prostate cancer has spread to one or more areas in the bones. During RFA, the doctor uses a CT scan or ultrasound to guide a small metal probe into the area of the tumor. A high-frequency current is passed through the probe to heat and destroy the tumor. RFA has been used for many years to treat tumors in other organs such as the liver, but its use in treating bone pain is still fairly new. Still, early results are promising.

Magnetic Resonance Imaging With Hyperpolarized Pyruvate As Diagnostic Tool In Advanced Prostate Cancer

open to eligible males ages 18 years and up

This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging as a diagnostic and response monitoring tool in patients with advanced prostate cancer. Preliminary pre-clinical and clinical data demonstrates the ability of HP C-13 pyruvate/metabolic MR imaging to detect high-grade prostate cancer, including cancer with neuroendocrine differentiation, as well as provide early evidence of metabolic response and resistance following application of systemic therapies for the treatment of advanced prostate cancer patients. In the proposed study, the investigators aim is to extend the initial clinical results and further develop HP C-13 MRI as an imaging modality in advanced prostate cancer.

San Francisco, California

You May Like: How To Get A Biopsy Of The Prostate

Enzalutamides Potential Impact On Pd

Patients with prostate cancer who are progressing on enzalutamide have been shown to have higher levels of PD-L1 on dendritic cells and PD-1 positive T cells relative to patients who have not received enzalutamide or who are responding to it . This creates interest in combining enzalutamide with immunotherapy to enhance response to PD-1 blockade potentially. Several trials have evaluated this combination with conflicting results.

A 2016 Phase II study evaluated this combination of immuno-hormonal therapy with enzalutamide and pembrolizumab in patients with mCRPC . Patients were eligible if they had evidence of progressive disease on enzalutamide, either in the form of rising PSA or radiographic progression. Patients were continued on enzalutamide and were given pembrolizumab every 3 weeks for four doses total. Ultimately, 58 patients were evaluated.

Given the findings that patients who are no longer responding to enzalutamide may have higher levels of PD-L1 positive dendritic cells, there are several ongoing studies exploring the combination of enzalutamide with pembrolizumab in an effort to augment response to PD-1 inhibition. Phase III trials Keynote-991 and Keynote-641 are currently enrolling. Keynote-641 will evaluate the combination of enzalutamide and pembrolizumab vs. enzalutamide and placebo , whereas Keynote-991 will explore this combination in patients who are hormone-sensitive .

Research In Prostate Cancer

We are always learning more about cancer. Researchers and healthcare professionals use what they learn from research studies to develop better practices that will help prevent, find and treat prostate cancer. They are also looking for ways to improve the quality of life of people with prostate cancer.

The following is a selection of research showing promise for prostate cancer. Weve included information from PubMed, which is the research database of the National Library of Medicine. Each research article in PubMed has an identity number that links to a brief overview . We have also included links to abstracts of the research presented at meetings of the American Society of Clinical Oncology , which are held throughout the year. You can find information about ongoing clinical trials from CanadianCancerTrials.ca and ClinicalTrials.gov. Clinical trials are given an identifier called a national clinical trial number. The NCT number links to information about the clinical trial.

You May Like: What Is The Last Stage Of Prostate Cancer

Search Strategy And Selection Criteria

This study comprehensively analyzed all the active or completed clinical trials of drug therapeutics for PC from January, 2010, to January 1, 2020, worldwide and in China. The details of the trials were obtained from Pharmaprojects, a drug development database developed by INFORMA . Pharmaprojects harbors more than 40,000 public sources, including Clinicaltrials.gov and Gene Therapy Clinical Trials Worldwide, as well as many other sources. The following search keywords were used: .

Two Studies For Patients With High Risk Prostate Cancer Testing Less Intense Treatment For Patients With A Low Gene Risk Score And Testing A More Intense Treatment For Patients With A High Gene Risk Score The Predict

open to eligible males ages 18 years and up

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.

San Mateo, California

Recommended Reading: Rezum Therapy For Enlarged Prostate

Testing The Safety Of Different Doses Of Olaparib Given Radium

open to eligible males ages 18 years and up

This phase I/II trial studies the best dose and side effects of olaparib and how well it works with radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to the bone and other places in the body . PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can’t repair themselves, and they may stop growing. Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Giving olaparib and radium Ra 223 dichloride may help treat patients with castration-resistant prostate cancer.

La Jolla, California

Testing Two Oral Drugs Combination Compared To A Single Drug For Men With Advanced Prostate Cancer

Sorry, in progress, not accepting new patients

This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body . PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can’t repair themselves, and they may stop growing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving olaparib and cediranib may help treat patients with castration-resistant prostate cancer.

La Jolla, California

You May Like: Prostagenix Vs Super Beta Prostate

Analysis Of Clinical Trials In Mainland China

The clinical investigations on the use of therapeutic drugs for PC in mainland China and worldwide were compared. In mainland China, 31 trials were completed in the last 10 years, including 21 on endocrine therapy, six on chemotherapy, three on radiotherapy, and one on immunotherapy. Most of these trials were phase III or phase IV trials , whereas only 12 were phase I or II trials . The therapeutic targets in each of these trials were identified . Endocrine therapy targets included androgen receptor , gonadotropin-releasing hormone , and cytochrome p450c17 . Chemotherapy targets included microtubules , poly polymerase , PKC , and S100A9 . All three radiotherapy trials used radium-223 to target actively dividing cancer cells . The single immunotherapy trial was a T-cell therapy targeting NY-ESO-1. China differs from other regions of the world in that drug targets in mainland Chinainitiated trials are limited. Moreover, the number of organizations conducting clinical trials on PC therapies is relatively low these trials were mainly done in large cities such as Shanghai, Beijing, Guangzhou, and Chengdu .

Figure 3 Prostate cancer therapy trial classification and geographical locations. Therapy type and targets for PC in clinical trials in mainland China. Cities with organizations for PC drug clinical trials .

Find A Ucla Clinical Trial

To search for clinical trials at UCLA, please visit UCLA Health’s online clinical trial search tool. You can also call the Clinical Trials Hotline at 731-6040. Fill out a short questionnaire and we can help match you to our clinical studies: Questionnaire >

The UCLA Institute of Urologic Oncology prides itself on being able to offer patients access to ground-breaking experimental drugs in its Clinical Trials Program that allows patients to receive tomorrows approved drugs today.

You May Like: Stage 4 Prostate Cancer Symptoms

Nivolumab + Docetaxel + Adt In Mhspc Patients With Ddrd Or Inflamed Tumors

open to eligible males ages 18 years and up

This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: – Androgen deprivation therapy with a drug of your physician’s choice. This may include leuprolide , goserelin acetate , or degarelix . – Docetaxel – Nivolumab

La Jolla, California

The Indicate Study Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide And Targeted Radiation Based On Pet/ct Imaging

Do you have prostate cancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. In the EA8191/INDICATE study, all participants will receive the usual treatment for prostate cancer that recurs after surgery, which is radiation therapy to the prostate bed and pelvic lymph nodes, combined with short-term androgen deprivation therapy , also sometimes referred to as hormone therapy. In addition:

Some patients will receive additional PET/CT imaging, depending on the results of their initial PET/CT scan. Some patients will also receive a type of hormone therapy called apalutamide, which is approved by the FDA for treatment of your prostate cancer. Some patients, depending on the results of their initial PET/CT scan, will receive metastasis-directed radiation therapy.

To decide which of these approaches is better, doctors on the study team will be looking to see if your cancer responds, and if it returns again, how much time passes after your treatment before it returns.

To learn more about this study and to find out if you may be eligible, please visit:

ClinicalTrials.gov identifier: NCT04423211

Recommended Reading: Lower Back Pain And Prostate Problems